Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial

The single-arm, phase 2 PACIFIC-6 trial (NCT03693300) found that durvalumab after sequential chemoradiotherapy (sCRT) had comparable safety profile to concurrent chemoradiotherapy reported by the PACIFIC trial (NCT02125461) and revealed encouraging efficacy for stage III, unresectable NSCLC. 1 Garassino M.C. Mazieres J. Reck M. et al. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022; 17: 1415-1427https://doi.org/10.1016/j.jtho.2022.07.1148 Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar ,2 Antonia S.J. Villegas A. Daniel D. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017; 377: 1919-1929 Crossref PubMed Scopus (2926) Google Scholar The current study adds new evidence to the utility of durvalumab after sCRT and addresses its safety profile; however, we have some claims before its clinical use.